Provided by Tiger Trade Technology Pte. Ltd.

Biogen

225.88
-1.1900-0.52%
Post-market: 225.880.00000.00%16:56 EDT
Volume:1.55M
Turnover:352.49M
Market Cap:33.35B
PE:40.12
High:229.36
Open:227.23
Low:225.51
Close:227.07
52wk High:230.49
52wk Low:138.00
Shares:147.64M
Float Shares:147.31M
Volume Ratio:1.30
T/O Rate:1.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.63
EPS(LYR):8.79
ROE:4.58%
ROA:5.21%
PB:1.77
PE(LYR):25.70

Loading ...

Compass Pathways Names Kelley Boucher Chief People Officer

Reuters
·
Yesterday

Analysts Conflicted on These Healthcare Names: Harmony Biosciences Holdings (HRMY), BioNTech SE (BNTX) and Biogen (BIIB)

TIPRANKS
·
Sep 26

Pharmaceutical Stocks Jump. Moderna, Eli Lilly up over 3%; Novavax, Pfizer up Around 2%; Merck, Novo Nordisk up over 1%

Tiger Newspress
·
Sep 24

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 22

Analysts Offer Insights on Healthcare Companies: Neuronetics (STIM), Xenon (XENE) and Biogen (BIIB)

TIPRANKS
·
Sep 18

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 18

Biogen publishes results from adolescent subgroup of VALIANT study

TIPRANKS
·
Sep 18

Eisai, Biogen announce Leqembi Pen has been approved in Japan

TIPRANKS
·
Sep 16

US FDA Approves Scholar Rock's Muscle Weakness Drug

Reuters
·
Sep 12

Biogen Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 11

Biogen Inc. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Sep 09

This Biotech Wins a Big FDA Approval. Why Wall Street is Shrugging.

Dow Jones
·
Sep 05

Correction: Eisai, Biogen Secure China's Nod for Self-Injection Version of Leqembi

MT Newswires Live
·
Sep 04

Stoke Therapeutics, Biogen present long-term data on Zorevunersen

TIPRANKS
·
Sep 04

Stoke Therapeutics, Biogen Report 4-Year Open-Label Data for Dravet Drug Zorevunersen Showing Durable Seizure Reduction

Reuters
·
Sep 04

Stoke Therapeutics and Biogen Present Long-Term Clinical Data That Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16TH European Epilepsy Congress (Eec)

THOMSON REUTERS
·
Sep 04

Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

GlobeNewswire
·
Sep 04

Biogen Price Target Raised to $245.00/Share from $225.00 by Piper Sandler

Dow Jones
·
Sep 04

Piper Sander Adjusts Biogen Price Target to $245 From $225, Maintains Overweight Rating

MT Newswires Live
·
Sep 03

Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi

TIPRANKS
·
Sep 03